Jefferies’s $930 target on REGN

REGN Regeneron Pharmaceuticals

$735 → $930 (+27%) by Oct 2027

Buy · raises · said Oct 1, 2026 · 12-month default horizon

Open: judged on the close on Oct 1, 2027

The article this target came from

Jefferies raises Regeneron stock price target to $930 on partnership

Investing.com · Oct 1, 2026

Jefferies raised its price target on Regeneron Pharmaceuticals shares (NASDAQ:REGN) to $930 from $870 while maintaining a Buy rating on Thursday

Jefferies’s track record → Regeneron Pharmaceuticals →

A fact about what Jefferies published, as reported by Investing.com, not a recommendation from Dalsna Finance; Jefferies is not affiliated with this site.

Full methodology: how targets are collected, scored, ranked and corrected, what each field means, and how to cite the data.